A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
All of the Dana Farber Cancer Institute clinicians – radiologists, pathologists, medical oncologists, surgeons, radiation oncologists and nursing staff – have deep experience treating your particular type of cancer. Their multidisciplinary team approach to cancer care ensures that you will receive the combination of treatments that is best for you.
Washington, District of Columbia Clinical Trial Location
Dana Farber Cancer Institute
450 Brookline Ave,
Boston, MA 02215